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The Inhibitory Receptor LIR-1 Uses a Common
Binding Interaction to Recognize Class I MHC
Molecules and the Viral Homolog UL18
NK cell inhibitory receptors engage an adequate level
of class I molecules on the target cell. Thus, the host
immune system ensures that those cells that have down-
regulated their class I MHC molecules to a level suffi-
cient to avoid detection by T cells can be recognized
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the host immune response, HCMV expresses UL18, a
class I MHC homolog (Beck and Barrell, 1988). The pre-
dicted extracellular portion of UL18 can be divided intoSummary
three domains (a1, a2, and a3) that share z25% amino
acid sequence identity with their class I counterparts.LIR-1 is a class I MHC receptor related to natural killer
Like host class I molecules, UL18 associates with b2minhibitory receptors (KIRs). Binding of LIR-1 or KIRs
(Browne et al., 1990) and endogenously derived pep-to class I molecules results in inhibitory signals. Unlike
tides (Fahnestock et al., 1995). UL18 was proposed toindividual KIRs, LIR-1 recognizes many class I alleles
function as a decoy class I molecule capable of bindingand also binds UL18, a human cytomegalovirus class
NK cell inhibitory receptors and preventing lysis of in-I MHC homolog. Here, we show that LIR-1 interacts
fected cells lacking surface class I expression (Fahne-with the relatively nonpolymorphic a3 domain of class
stock et al., 1995). However, the host cell ligand of UL18I proteins and the analogous region of UL18 using its
was identified as leukocyte immunoglobulin-like recep-N-terminal immunoglobulin-like domain. The .1000-
tor-1 (LIR-1 or ILT2), a membrane glycoprotein ex-fold higher affinity of LIR-1 for UL18 than for class
pressed on only a subset of NK cells (Cosman et al.,I illustrates how a viral protein competes with host
1997) and most or all monocytes, dendritic and B cells,proteins to subvert the host immune response. LIR-1
and some T cells (Borges et al., 1997; Colonna et al.,recognition of class I molecules resembles the CD4±
1997; Fanger et al., 1998). LIR-1 is a member of a familyclass II MHC interaction more than the KIR±class I
of proteins (LIR-1 to LIR-8) that contain two or fourinteraction, implying a functional distinction between
extracellular immunoglobulin (Ig)-like domains relatedLIR-1 and KIRs.
to NK cell killer inhibitory receptor (KIR) domains (Borges
et al., 1997). The endogenous ligands of LIR-1, LIR-2,Introduction
and KIRs are class I MHC molecules. However, while
individual KIRs show allele-specific recognition of classHuman cytomegalovirus (HCMV) is a widespread infec-
I molecules, LIR-1 and LIR-2 interact with a broad rangetious agent that infects 70%±90% of immunocompetent
of classical and nonclassical class I MHC molecules
adults (Wentworth and Alexander, 1971). While primary
(Fanger et al., 1998; Navarro et al., 1999; Vitale et al.,
infection elicits an immune response, the response is
1999). Despite a high level of sequence identity between
insufficient to clear the virus, and lifelong infection en- LIR family members, only LIR-1 binds UL18 (Borges et
sues. To maintain viral persistence in the presence of a al., 1997).
fully primed immune system, HCMV has evolved strate- The role of LIR-1 in the immune response to viruses
gies that subvert the host immune system, including in general and HCMV in particular has not yet been
downregulation of cell surface expression of host class elucidated, but LIR-1 shows properties consistent with
I MHC molecules (reviewed in Wiertz et al., 1997). Class an inhibitory function. In common with KIRs, several LIR
I MHC molecules are heterodimers composed of a poly- proteins contain inhibitory motifs in their cytoplasmic
morphic membrane-bound heavy chain associated with tails, and LIR-1 associates with SHP-1, a tyrosine phos-
the nonpolymorphic light chain b2-microglobulin (b2m). phatase that inhibits activating signals (Cosman et al.,
Peptides derived from degradation of cytoplasmic pro- 1997). LIR-1 engagement on NK and T cells by class I
teins are presented to cytotoxic T cells bound to class MHC molecules protects target cells from lysis, and
I molecules in a groove within the a1 and a2 domains concurrent recognition of LIR-1 with other receptors
of the heavy chain (reviewed in Bjorkman and Parham, results in inhibition of intracellular Ca21 mobilization (Co-
1990). While downregulation of surface class I expres- lonna et al., 1997). These studies demonstrate that LIR-1
sion hinders recognition of infected cells by virus-spe- can function as an inhibitory receptor and might there-
cific T cells, cells that lack surface class I MHC expres- fore modulate activation signals in response to recogni-
sion are potential targets for natural killer (NK) cells. tion of host cell class I molecules or UL18.
NK cells express activating receptors, which can be To better understand the functions of UL18 in evasion
triggered by both non-MHC and MHC molecules, and of the host immune response and LIR-1 in the presence
inhibitory receptors, which recognize class I MHC mole- and absence of CMV infection, we characterized the
cules (reviewed in Lanier et al., 1997). Stimulation of LIR-1/UL18 and LIR-1/class I MHC interactions. We find
activating receptors leads to target cell lysis unless the that LIR-1 binds UL18 with greater than 1000-fold higher
affinity than it binds classical and nonclassical class I
proteins; thus, even low levels of UL18 can efficiently³ To whom correspondence should be addressed (e-mail: bjorkman@
cco.caltech.edu). compete with residual host cell class I proteins on
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Figure 1. Characterization of Proteins
(A) Purified proteins analyzed on 15% reduc-
ing SDS-PAGE. The z10 kDa contaminant in
the D1D2 and D1 preparations is not respon-
sible for the observed interaction between
D1D2 and UL18 or D1 and UL18, since it is
not coprecipitated with UL18 and either LIR-1
fragment using reagents that bind to UL18
(an anti-b2m monoclonal antibody or Ni-NTA
beads) (data not shown).
(B) Thermal denaturation of peptide-filled and
empty forms of UL18-CC monitored by the
CD signal at 223 nm. Transition midpoints
(Tm), 358C, empty UL18-CC; 608C, peptide-
filled UL18-CC.
HCMV-infected cells for LIR-1 binding. The primary (Davis et al., 1993). A previously identified UL18-binding
peptide (Fahnestock et al., 1995) was added to insectbinding site on LIR-1 for both class I molecules and
UL18 is its N-terminal domain, and this region interacts cell supernatants, resulting in peptide-filled UL18, here-
after referred to as UL18-high mannose or UL18-HMwith the a3 domain of class I proteins and UL18. Recog-
nition of the a3 domain, which is relatively nonpolymor- (see the Experimental Procedures). The heavy chains of
UL18-CC and UL18-HM migrate with different apparentphic, predicts that LIR-1 can interact with most or all
class I MHC molecules, consistent with previous obser- molecular masses on an SDS-acrylamide gel: 77 to 97
kDa for UL18-CC and 50 to 53 kDa for UL18-HM (Figurevations that LIR-1 binds a wide range of class I proteins
(Colonna et al., 1997; Lanier et al., 1997; Fanger et al., 1A), consistent with molecular weights derived by mass
spectrometry (76 kDa for UL18-CC and 57 kDa for UL18-1998; Navarro et al., 1999). These results suggest that
LIR-1 differs in recognition properties from KIRs, sharing HM; data not shown). The molecular weight difference
indicates that the two forms of UL18 differ in the compo-more characteristics with the T cell coreceptor CD4-
class II MHC interaction than with the KIR-class I MHC sition of carbohydrates attached to potential N-linked
glycosylation sites.interaction.
Results Production of Soluble Forms of LIR-1 Containing
One, Two, and Four Ig-like Domains
The extracellular region of LIR-1 comprises four Ig-likeProduction of Peptide-Filled, Empty, and Different
Carbohydrate-Containing Forms of Soluble UL18 domains (D1, D2, D3, and D4). A soluble version of the
entire extracellular region (D1-D4) was expressed inWe previously demonstrated that soluble UL18 pro-
duced in CHO cells associates with endogenously de- baculovirus-infected insect cells. Equilibrium analytical
ultracentrifugation demonstrated that purified D1-D4 isrived peptides (Fahnestock et al., 1995). To investigate
the role of bound peptide in LIR-1 recognition of UL18, monomeric at mM concentrations (data not shown). To
determine which region of LIR-1 interacts with UL18 andwe prepared peptide-filled and empty forms of soluble
UL18-human b2m heterodimers produced in CHO cells class I MHC molecules, we prepared smaller versions
of LIR-1 corresponding to single domains (D1, D2, and(hereafter referred to as UL18-complex carbohydrate or
UL18-CC [see below]) (Figure 1A). The empty form of D3) or tandem domains (D1D2 and D3D4) (see the Exper-
imental Procedures). All of the fragments run in the ex-UL18-CC was prepared by removing endogenous pep-
tides from the peptide-filled form under denaturing con- pected position on a gel filtration column, and far UV
circular dichroism (CD) spectra indicate that each frag-ditions and then refolding the protein in the absence of
peptide. Empty UL18-CC is thermally unstable com- ment contains mainly b-sheet secondary structure (data
not shown); thus, the fragments retain their native folds.pared with the peptide-filled form (Figure 1B).
The extracellular portion of the UL18 heavy chain con- These results suggest that interdomain interactions are
not required for correct folding of the LIR-1 domainstains 13 potential N-linked carbohydrate sites (Beck and
Barrell, 1988). The majority of these sites appear to be and are consistent with an elongated structure for D1-
D4 (Figure 5).utilized when the protein is produced in infected or
transfected cells since the heavy chain migrates on SDS
polyacrylamide gels with a higher than predicted appar- LIR-1 and UL18 Form a 1:1 Complex in Solution
To determine the stoichiometry of the interaction be-ent molecular mass (Browne et al., 1990; Fahnestock et
al., 1995; Leong et al., 1998) (Figure 1A). Because a large tween UL18 and LIR-1 in solution, various molar ratios
of UL18-HM and D1-D4 were passed over a Superoseproportion of the surface of UL18 is likely to be occluded
by carbohydrate, we wished to examine the role of car- 6B column. When UL18-HM and D1-D4 were present at
equimolar ratios, a single peak corresponding to thebohydrate in recognition of UL18 by LIR-1. We therefore
expressed UL18 in insect cells, which attach high man- UL18/LIR-1 complex eluted from the column (Figure 2).
The 1:1 stoichiometry of the UL18/LIR-1 complex wasnose or truncated trimannosyl N-linked glycans (Jenkins
et al., 1996), to compare with UL18 produced in CHO verified by equilibrium analytical ultracentrifugation,
which yielded molecular weights of 59 kDa (UL18-HM),cells, which attach complex N-linked carbohydrates
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either orientation demonstrate that the presence or ab-
sence of peptide and the nature of the carbohydrate on
UL18 have little effect on binding LIR-1. These results
suggest that the LIR-1 binding site on UL18 primarily
involves a protein, rather than carbohydrate, portion of
UL18 that is distinct from the peptide-binding site.
We also derived affinities for the interaction of D1-D4
with soluble versions of classical and nonclassical class
I MHC molecules (Figures 3C and 3D; Table 1). The MHC
proteins used in these binding assays contained either a
mixture of endogenous peptides (HLA-B*2702) or single
defined peptides (HLA-Cw*0602, HLA-Cw*0301, HLA-
Cw*0702, HLA-G1, HLA-E). The proteins were either un-
glycosylated (HLA-Cw*0602, HLA-Cw*0301, HLA-G1,
HLA-E) or included complex N-linked glycans (HLA-
B*2702, expressed in CHO cells) or high mannose or
truncated trimannosyl N-linked glycans (HLA-Cw*0702,
expressed in insect cells). Each class I protein was im-
mobilized to a flowcell on a biosensor chip, and D1-
D4 was injected. Most of the binding reactions were
assayed only in this orientation because the class I pro-
teins were not generally available in sufficient quantities
to allow injections over immobilized D1-D4. We also
coupled soluble HFE, a b2m-containing heterodimer that
is structurally similar to class I MHC proteins (LebroÂ n et
al., 1998), to a similar density. We observed small but
significant binding responses for high concentrations
of D1-D4 injected over the immobilized classical and
nonclassical class I proteins, but no significant response
for injections over the HFE coupled flowcell (Figure 3C).
We also found no significant binding of D1-D4 to soluble
versions of two other human class I MHC homologs,
Figure 2. Gel Filtration Chromatographic Demonstration that UL18 FcRn and ZAG (SaÂ nchez et al., 1999) (data not shown).
and D1-D4 Bind with 1:1 Stoichiometry To account for nonspecific interactions, the binding re-
UL18-HM and D1-D4 were incubated at the indicated molar ratios sponse at equilibrium was calculated by subtracting the
and then passed over a sizing column to separate UL18:D1-D4
response seen in the HFE-coupled flow cell for eachcomplexes from free proteins. At a 1:1 molar ratio, virtually all of
concentration of injected D1-D4 (Figure 3D). Affinity con-the protein migrated as the complex. When the input ratio of UL18
stants derived from these data are summarized in Tableto D1-D4 was greater than 1:1, there was excess UL18, and when
it was less than 1:1, there was excess D1-D4. 1. The approximate KDs for the interaction of D1-D4
with the classical and nonclassical class I molecules we
tested range from 15 to 100 mM. Thus, LIR-1 binds to
these host class I proteins .1000-fold more weakly than55 kDa (D1-D4), and 96 kDa (UL18-HM/D1-D4 complex)
it binds to UL18.(data not shown).
LIR-1 Binds UL18 with Higher Affinity Than It Binds The Primary UL18 and Class I Binding Site on LIR-1
Is Located in D1to Class I MHC Proteins
We used a surface plasmon resonance (SPR)-based To localize the binding site(s) on LIR-1 for UL18 and
class I MHC proteins, we compared the binding of D1-assay to determine the affinities of the interactions be-
tween D1-D4 and the various forms of UL18. Empty D4 with fragments of LIR-1 composed of one or two
Ig-like domains. As summarized in Table 1, the D1D2UL18-CC, peptide-filled UL18-CC, and UL18-HM were
each immobilized on a biosensor chip, and the interac- fragment binds both UL18 and each of the class I pro-
teins tested with a similar affinity as D1-D4. In contrast,tion with injected D1-D4 was monitored (Figure 3A).
Binding of the various UL18 species over a D1-D4 cou- D3D4 showed no detectable binding to either UL18 or
any of the class I proteins (Figures 3B and 3E). To furtherpled biosensor chip was also assayed. As summarized
in Table 1, D1-D4 binds all forms of UL18 with an equilib- localize the binding site on LIR-1, we analyzed the bind-
ing of individual domains, D1 and D2, to UL18 and classrium dissociation constant (KD) in the nM range. There
is a slight coupling dependence to the derived affinities, I molecules. In all cases tested, D1 bound with only
slightly reduced affinity compared with D1D2 or D1-D4,such that injected LIR-1 binds immobilized UL18 with a
higher apparent affinity than injected UL18 binds immo- whereas D2 showed no detectable binding (Figures 3B
and 3E). These results indicate that the primary bindingbilized LIR-1. Coupling-dependent affinity differences
have been observed in other biosensor-based assays site on LIR-1 for both UL18 and class I MHC proteins
is located within D1, with the possibility of minor contri-(Kuziemko et al., 1996; LebroÂ n et al., 1998). For the UL18
interaction with D1-D4, affinity constants derived from butions from residues within D2. The finding that the
Immunity
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Figure 3. Biosensor Analyses of LIR-1-UL18
and LIR-1-Class I Binding
In each panel, the injected protein is indicated
in front of an arrow pointing to the immobi-
lized protein.
(A and B) Sensorgrams (thick colored lines)
from kinetics-based binding experiments
overlaid with the calculated response (thin
black lines) derived using a 1:1 binding
model. One representative set of injections
from experiments performed in triplicate is
shown for each interaction (analyses from
triplicate experiments reported in Table 1).
(C±E) Sensorgrams from binding experiments
in which the binding response closely ap-
proached or reached equilibrium. Plots of the
equilibrium binding response (Req) versus the
log of the concentration of injected protein
are shown to the right of each sensorgram
with best fit binding curves to the experimen-
tal data points shown as continuous lines.
Derived KD values are approximate because
binding is not saturated at the highest con-
centration of protein possible to achieve with
limited quantities of protein.
(A) D1-D4 injected over the three forms of
UL18.
(B) UL18-HM injected over smaller LIR-1 frag-
ments. No significant responses are seen for
UL18-HM injected over D3D4 or D2 (red sen-
sorgrams).
(C) Comparison of response for D1-D4 in-
jected over HLA-Cw*0702 or over HFE. No
significant response is seen for D1-D4 in-
jected over HFE (red sensorgrams).
(D) D1-D4 injected over classical and non-
classicial class I proteins. For each sen-
sorgram, the residual response from the HFE-
coupled flowcell (C) has been subtracted.
(E) HLA-Cw*0702 injected over smaller LIR-1
fragments. No significant responses are seen
for HLA-Cw*0702 injected over D3D4 or D2
(red sensorgrams).
same region of LIR-1 is used for binding both UL18 and and/or HFE. LIR-1 binding was assayed by staining with
His-tagged D1-D4 incubated with a FITC-labeled anti-class I molecules is consistent with the observation that
preequilibration of D1-D4 with UL18 blocks binding to His tag antibody. The D1-D4 reagent stained cells ex-
pressing wild-type UL18 and a1a2HFE-a3UL18 but notimmobilized HLA-Cw*0702 (data not shown).
cells expressing a1a2UL18-a3HFE or whole HFE (Figure
4A), indicating that the UL18 a3 domain is a primaryLIR-1 Interacts with the a3 Domain of Both UL18
and Class I Molecules interaction site for D1-D4.
To identify the LIR-1 binding site on a class I MHCTo identify which portion of UL18 is recognized by LIR-1,
we constructed domain-swapped proteins in which do- molecule, we made chimeras of HFE and the human
class I MHC molecule HLA-B*0702 (a1a2HFE-a3B7 andmains from HFE were exchanged into UL18. We made
the following four constructs: full-length (wild-type) ver- a1a2B7-a3HFE) to compare with full-length HLA-B*0702
and HFE. Protein expression was verified using antiserasions of UL18 and HFE and a1a2UL18-a3HFE and
a1a2HFE-a3UL18 (in which the a1 and a2 domains from against HFE or a class I MHC-specific monoclonal anti-
body. Although wild-type HLA-B*0702 and the B7-HFEthe first protein were fused to the a3, transmembrane,
and cytosolic domains of the second protein). Expres- swapped constructs were expressed in transfected
COS-7 cells (Figure 4B), none of the cells stained withsion in transfected COS-7 cells was verified by staining
live and fixed cells with polyclonal antisera against UL18 labeled D1-D4 (data not shown), which was used for
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Table 1. Biosensor Analyses of LIR-1 Binding to UL18 and Class I MHC Molecules
KD (M) ka (sec21M21) kd (sec21)
UL18 or Class I Immobilized
D1-D4→UL18-CC empty (8.3 6 0.5) 3 1029 (6.1 6 0.9) 3 105 (5.0 6 0.9) 3 1023
D1-D4→UL18-CC 1 peptide (2.9 6 0.3) 3 1029 (5.8 6 0.8) 3 105 (1.7 6 0.4) 3 1023
D1-D4→UL18-HM 1 peptide (4.0 6 3) 3 1029 (5.2 6 1) 3 105 (2.1 6 0.5) 3 1023
D1-D4→HLA-B*2702 (8, 9) 3 1025
D1-D4→HLA-Cw*0702 (2, 2) 3 1025
D1-D4→HLA-Cw*0602 (4, 5) 3 1025
D1-D4→HLA-Cw*0301 9 3 1025
D1-D4→HLA-G1 1 3 1024
D1-D4→HLA-E 4 3 1025
LIR-1 D1-D4 Immobilized
UL18-CC empty→D1-D4 (1.0 6 0.1) 3 1027 (1.1 6 0.3) 3 105 (1.1 6 0.2) 3 1022
UL18-CC 1 peptide→D1-D4 (2.1 6 0.5) 3 1028 (1.1 6 0.8) 3 105 (2.3 6 0.4) 3 1023
UL18-HM 1 peptide→D1-D4 (1.4 6 0.4) 3 1028 (1.5 6 0.5) 3 105 (2.1 6 0.6) 3 1023
HLA-Cw*0702→D1-D4 6 3 1025
UL18 and Class I MHC Binding to LIR-1 Domains
UL18-HM 1 peptide→D1D2 (1.6 6 0.3) 3 1028 (1.1 6 0.1) 3 105 (1.7 6 0.3) 3 1023
UL18-HM 1 peptide→D1 (6.1, 7.7) 3 1028 (8.0, 6.6) 3 105 (4.9, 5.1) 3 1022
UL18-HM 1 peptide→D2 NB
UL18-HM 1 peptide→D3 NB
UL18-HM 1 peptide→D3D4 NB
D1D2→HLA-B*2702 5 3 1025
D3D4→HLA-B*2702 NB
D1D2→HLA-Cw*0702 3 3 1025
HLA-Cw*0702→D1D2 3 3 1025
HLA-Cw*0702→D1 8 3 1025
HLA-Cw*0702→D2 NB
D3D4→HLA-Cw*0702 NB
D3D4→HLA-G1 NB
D3D4→HLA-E NB
The injected protein is indicated in front of an arrow pointing to the immobilized protein. When kinetic constants (ka and kd) are reported, the
binding data were fit to a 1:1 binding model, and the KD was determined as kd/ka. KDs were determined from three or four independent
measurements, and the numbers after the 6 sign represent standard deviations. When no kinetic constants are reported, the KD was determined
from equilibrium binding data fit to a 1:1 binding model. Experiments were performed in duplicate if two KD values are listed. Due to insufficient
quantities of protein, the highest LIR-1 or class I concentration used was 100 mM, which was not sufficient to saturate binding; thus, the KD
values for LIR-1 binding to class I molecules are approximate. NB, no binding detected.
the staining of the UL18 expressing cells (Figure 4A). and nonclassical class I molecules (Fanger et al., 1998;
Navarro et al., 1999; Vitale et al., 1999). In addition, LIR-1Assuming that the inability to stain with monomeric D1-
D4 resulted from a low affinity between D1-D4 and HLA- binds to UL18 (Cosman et al., 1997), a peptide-binding
class I MHC homolog encoded by HCMV (Beck andB*0702, as was found for the D1-D4 interaction with
other class I MHC proteins (Table 1), we used a bivalent Barrell, 1988; Fahnestock et al., 1995). The functions of
both LIR-1 and UL18 remain obscure. To address howversion of LIR-1 (a LIR-1 Fc fusion protein; LIR-1 Fc;
Cosman et al., 1997) in order to increase the avidity LIR-1 functions in the absence of HCMV infection and
the role of UL18 in HCMV evasion of the host immunebetween LIR-1 and HLA-B*0702. Labeled LIR-1 Fc stains
cells expressing wild-type HLA-B*0702 and a1a2HFE- response, we characterized the LIR-1 interaction with
class I MHC proteins and with UL18. Our studies reveala3B7 but not cells expressing a1a2B7-a3HFE or wild-
type HFE (Figure 4B). We conclude that LIR-1 interacts the molecular basis for the broad class I±binding speci-
ficity of LIR-1 and shed light on the function of UL18.primarily with the a3 domain of HLA-B*0702 and that
this interaction is of lower affinity than the LIR-1 interac- Using soluble versions of LIR-1 and class I MHC pro-
teins, we found weak but significant binding betweention with the a3 domain of UL18.
the LIR-1 extracellular region (D1-D4) and every class I
protein tested, including three HLA-C alleles, one HLA-BDiscussion
allele, and the nonclassical class I molecules HLA-G1
and HLA-E. These results are in general agreement withLIR-1 is an inhibitory receptor that is expressed on a
majority of B cells, monocytes, and dendritic cells, and binding and functional studies demonstrating LIR-1 in-
teraction with a broad range of class I proteins includinga small subset of NK and T cells (Borges et al., 1997;
Colonna et al., 1997; Cosman et al., 1997; Vitale et al., HLA-G (Fanger et al., 1998; Navarro et al., 1999; Vitale
et al., 1999) but are in apparent contrast with previous1999). Like the KIR and Ly49 families of NK inhibitory
receptors (Lanier et al., 1997), LIR-1 binds class I MHC reports that the LIR-1 Fc fusion protein does not bind
HLA-Cw*0702 (Fanger et al., 1998) and that HLA-E doesmolecules, resulting in inhibition of activation signals
(Colonna et al., 1997; Navarro et al., 1999). Unlike these not induce LIR-1-mediated inhibition in a functional
assay (Navarro et al., 1999). We find that D1-D4 bindsNK receptors, which bind with allelic specificity (Lanier
et al., 1997), LIR-1 binds to a broad range of classical to these alleles, but these binding events might not be
Immunity
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Figure 4. Staining of Transfected COS-7
Cells
Fixed cells were stained with the indicated
FITC-labeled antibody or antiserum (green)
to verify expression and with a Cy-3-labeled
antibody bound to D1-D4 ([red]; cells ex-
pressing UL18-containing proteins) or LIR-1
Fc ([red]; cells expressing HLA-B*0702-con-
taining proteins; magnification, 633, zoomed
twice). Staining of live cells verified that the
constructs are expressed at the cell surface
(data not shown).
detected using other assays and may have no functional interaction with the two types of protein are similar. For
both UL18 and class I proteins, the primary binding siteconsequences. Although D1-D4 binds to every classical
and nonclassical class I protein tested in our assay, it on LIR-1 is within the first of its four Ig-like domains.
Thus, a fragment corresponding to the N-terminal do-does not bind to HFE, FcRn, or ZAG, class I MHC homo-
logs that are structurally but not functionally similar to main alone (D1) binds with similar affinity as the entire
extracellular region of LIR-1 (D1-D4) (Table 1). This prop-members of the class I MHC family that function in anti-
gen presentation to T cells (LebroÂ n et al., 1998; SaÂ nchez erty distinguishes LIR-1 from p58 KIRs, whose binding
site for class I molecules is at the interface between theet al., 1999). Thus, LIR-1 is specific for peptide-binding
class I molecules that function in the immune system, first and second Ig-like domains (Lanier et al., 1997).
Indeed, the structure of the D1D2 portion of LIR-1 issupporting the proposed role of UL18 as a virally-
encoded immunomodulator. likely to be different from the structures of p58 KIRs, in
which an acute angle relating KIR D1 and D2 createsThe LIR-1 interaction with host class I MHC proteins
is considerably weaker than its interaction with the viral extensive interaction between the domains (Fan et al.,
1997). The observation that D1D2 can be cleaved intoclass I homolog UL18. D1-D4 binds to UL18 with a KD
in the nM range but binds to classical and nonclassical stable fragments corresponding to D1 and D2 (Figure
1) suggests that there are not extensive interdomainclass I molecules with .1000-fold reduced affinity (Table
1). The extensive N-linked glycosylation of UL18 (Beck interactions in this portion of LIR-1. A second similarity
in LIR-1 recognition of its viral and host ligands is thatand Barrell, 1988) compared to that of class I molecules
(Bjorkman and Parham, 1990) suggested a possible ex- LIR-1 recognizes the a3 domain of both UL18 and class
I molecules. In this respect, LIR-1 also differs from KIRs,planation for the increased affinity of LIR-1 for UL18
compared to its affinity for class I molecules. However, which bind to an epitope within the a1-a2 region of class
I molecules (Lanier et al., 1997). In class I proteins, theLIR-1 binds different carbohydrate-containing forms of
UL18 with nearly equal affinities (Table 1), suggesting a3 domain is relatively conserved between different al-
leles as compared with the polymorphic a1-a2 peptide-that LIR-1 primarily recognizes a protein, rather than
carbohydrate, epitope on UL18 and class I molecules. binding region (Bjorkman and Parham, 1990), providing
a rationalization for the broad binding specificity of LIR-1The recognition is independent of bound peptide, since
LIR-1 binds to peptide-filled and empty UL18 with similar compared with individual KIRs.
Our data suggest that the interaction between LIR-1affinities (Table 1).
Although LIR-1 binds UL18 with much higher affinity and class I molecules and the class I±related protein
UL18 can be schematically diagrammed as shown inthan it binds class I proteins, other aspects of the LIR-1
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Figure 5. Schematic Comparison of the
LIR-1±Class I, KIR±Class I, and CD4±Class II
Interactions
D1-D4 is likely to have an elongated structure
with minimal interdomain interactions (see
text). LIR-1 binds to the a3 domain of UL18
and class I proteins using its N-terminal do-
main (see text), analogous to the interaction
between D1 of CD4 and the b2 domain of
class II MHC proteins (Leahy, 1995). By con-
trast, KIRs are bent, with extensive interdo-
main interactions, and bind to a region on
the class I a1 domain using residues at the
interface between domains (Fan et al., 1997;
Lanier et al., 1997).
Figure 5. Based upon the ability of isolated LIR-1 do- antiviral immune response. Expression of UL18 by HCMV-
infected cells may be a mechanism whereby HCMVmains to fold stably, we assume that there are not exten-
sive interdomain interactions and therefore depict LIR-1 avoids the consequences of downregulating LIR-1 li-
gands. In this respect, the high affinity between LIR-1as a four domain extended structure. In contrast, p58
KIR domains are arranged in a kinked structure with and UL18 may be significant, in that only a small amount
of UL18 on infected cells should be sufficient to bindextensive interdomain interactions, as revealed by crys-
tal structures (e.g., Fan et al., 1997). Based upon our LIR-1 resulting in inhibition. Indeed, only small amounts
of UL18 are expressed on the surfaces of transfectedbinding analyses, we show a 1:1 complex in which LIR-1
D1 interacts with the a3 domain of UL18 and class I or HCMV-infected cells (Leong et al., 1998); thus, a high
affinity interaction with LIR-1 would be required for UL18molecules. This interaction is reminiscent of the interac-
tion between CD4 and class II MHC molecules, in that to exert an effect.
UL18 probably evolved from a host cell class I MHCthe class II binding site is localized primarily on the
CD4 N-terminal domain and CD4 binds to the class II gene acquired by HCMV at some point during its evolu-
tion with its human host (Wiley, 1988). While UL18 hascounterpart of the class I a3 domain (class II b2) (re-
viewed in Leahy, 1995). In its properties, LIR-1 can be greatly diverged from class I MHC molecules, as evi-
denced by sharing only z25% amino acid sequencethought of as a hybrid between KIRs and the T cell
coreceptors CD4 and CD8. Like KIRs, LIR-1 functions identity (Beck and Barrell, 1988), it has retained and
improved upon the class I property of binding the inhibi-as an inhibitory receptor and binds weakly to class I
MHC molecules (KIR-class I MHC affinities are z 10 mM) tory receptor LIR-1. The higher affinity of LIR-1 for UL18
than for class I molecules provides an example of how(ValeÂ s-GoÂ mez et al., 1998), but like the T cell corecep-
tors, LIR-1 responds to a region on MHC molecules that a viral protein is able to compete efficiently with host
proteins to subvert the host immune response.does not involve the peptide-binding domains recog-
nized by T cell receptors or KIRs.
The low affinity of the interaction between LIR-1 and Experimental Procedures
class I MHC molecules suggests that high local concen-
trations of class I molecules need to be present to trigger Production of Peptide-Filled, Empty, and Different
Carbohydrate-Containing Forms of UL18LIR-1-mediated inhibition. However, class I MHC mole-
We previously described the purification of a soluble form of UL18cules are downregulated by HCMV infection (Wiertz et
(residues 1±284 of the mature UL18 heavy chain complexed withal., 1997). In the absence of a mechanism to engage
human b2m) from the supernatants of transfected CHO cells (Fahne-host cell LIR-1 molecules, B cells, monocytes, and den- stock et al., 1995; Chapman and Bjorkman, 1997). For the experi-
dritic cells would presumably be activated by a lower ments described here, we modified the UL18 construct to include
a C-terminal 6x-His tag. The modified UL18 gene was sequencedthreshold of stimulatory signals, leading to a stronger
Immunity
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and subcloned into PBJ5-GS, which carries the glutamine synthe- MQPTHPIRL for HLA-G [Lee et al., 1995]). Refolded class I hetero-
dimers were purified from aggregates and free b2m by gel filtrationtase gene as a selectable marker and means of gene amplification in
the presence of methionine sulfoximine (Bebbington and Hentschel, chromatography using a Superdex 200 column.
HLA-Cw*0301 and HLA-Cw*0602 were provided by Dr. Jongsun1987). Selection and amplification of UL18-expressing cells were
done as described (Chapman and Bjorkman, 1997). UL18-CC was Kim (Yonsei University College of Medicine, Seoul, Korea). These
proteins were expressed in E. coli and refolded from inclusion bodiespurified from the supernatants of transfected CHO cells using Ni-
NTA chromatography (Ni-NTA superflow, Qiagen) followed by immu- as described (Kim et al., 1997).
Soluble human FcRn (A. P. West and P. J. B., unpublished data),noaffinity chromatography using a column constructed with the anti-
b2m monoclonal antibody BBM.1 (Parham et al., 1983) as described ZAG (SaÂ nchez et al., 1999), and HFE (LebroÂ n et al., 1998) were
expressed and purified (in the case of FcRn and HFE) or purified(Fahnestock et al., 1995). Although soluble UL18 expressed in CHO
cells contains endogenous peptides (Fahnestock et al., 1995), over- from human serum (in the case of ZAG) as described.
All of the classicial, nonclassical, and class I±like MHC moleculesexpression of UL18 leads to secretion of some protein that is either
empty or does not contain an optimal peptide (Chapman and Bjork- migrated in the expected positions on a gel filtration column and
were at least 95% pure as judged by SDS-PAGE (data not shown).man, 1997). To ensure that all UL18-CC includes a bound peptide,
a synthetic peptide (ALPHAILRL) corresponding to a portion of actin, After immobilization on a biosensor chip (see below), the HLA-B,
HLA-Cw, HLA-E, and HLA-G proteins were recognized by W6/32, awhich was previously shown to be a major component of UL18 acid
eluates (Fahnestock et al., 1995), was added during purification of monoclonal antibody that binds to correctly folded classical and
nonclassical class I heterodimers (Parham et al., 1979), and FcRnUL18-CC.
Empty UL18-CC was prepared from peptide-filled UL18-CC as and HFE bind to their ligands (IgG and transferrin receptor, respec-
tively) (A. P. West and P. J. B., unpublished data; LebroÂ n et al., 1998)described for H-2Kd (Fahnestock et al., 1992). In brief, UL18-CC/
b2m heterodimers were denatured in 6.0 M guanidine hydrochloride (data not shown).
and separated from endogenous peptides by gel filtration chroma-
tography in 6.0 M guanidine hydrochloride on a Superdex 200 col-
Expression and Purification of LIR-1 Proteinsumn (Pharmacia). Heavy and light chain peaks were pooled and
D1-D4 was expressed in baculovirus-infected insect cells as de-renatured in the presence of an z3-fold excess of human b2m (ex-
scribed for UL18-HM. PCR was used to modify the cDNA encodingpressed in bacteria; see below) by dialysis against 20 mM Tris (pH
LIR-1 (gift of D. Cosman, Immunex) to introduce a stop codon and7.4), 150 mM NaCl, 1 mM EDTA, and 0.2 mM phenylmethanesulfonyl
a 6x-His tag after the codon for His458 (numbered according tofluoride containing 8.0 M urea, and then twice against the same
Cosman et al. [1997]; see our numbering scheme below). The modi-buffer without urea. Renatured material was concentrated in a Cen-
fied gene, which encodes the hydrophobic leader sequence andtricon-10 (Millipore) and passed over a Superdex 200 column. Frac-
residues 1 to 435 of the mature protein, was subcloned after se-tions corresponding to unaggregated UL18-CC/b2m heterodimers
quencing into the baculovirus transfer vector pVL1393 (Pharmacia).were pooled and concentrated.
D1-D4 was purified from supernatants of baculovirus-infected HighA form of soluble UL18 containing high mannose or truncated
5 cells using Ni-NTA and gel filtration chromatography as describedtrimannosyl N-linked carbohydrates (UL18-HM) was produced in
for HLA-Cw*0702. N-terminal sequence analysis yielded the se-baculovirus-infected insect cells. A construct encoding soluble
quence GHLPKPTLWAE; thus, the leader sequence was cleavedUL18 (corresponding to residues 1±284 of the mature protein with
during the secretion process. In our numbering scheme, the N-ter-the preceding hydrophobic leader sequence) plus a C-terminal Fac-
minal residue of the mature protein is residue 1; previous publica-tor Xa site and 6x-His tag was subcloned after sequencing into
tions referred to this glycine as residue 24 (Cosman et al., 1997).the dicistronic baculovirus transfer vector pAcUW31 (PharMingen).
D1D2 (an initial methionine plus residues 1±197 of the maturecDNA encoding human b2m plus its hydrophobic leader sequence
protein) was expressed in E. coli strain BL21(DE3)pLysS using thewas subcloned into the second multiple cloning site of the transfer
expression vector pEt23a (Novagen). The protein was renaturedvector. Recombinant baculovirus was generated by cotransfection
from inclusion bodies as described (Garboczi et al., 1996). The N-ter-of the transfer vector with linearized viral DNA (Baculogold; Phar-
minal sequence of purified D1D2 was GHLPKPTLWAE, the same asMingen). UL18-HM/b2m heterodimers were purified from superna-
that of D1-D4; thus, the methionine residue added to allow produc-tants of baculovirus-infected High 5 cells after adding the UL18-
tion inside E. coli was lost.binding peptide ALPHAILRL (Fahnestock et al., 1995) using Ni-NTA
To prepare D1 and D2, 1 mg of D1D2 was incubated in 50 mMand immunoaffinity chromatography as described for UL18-CC.
NaHCO3 and 100 mM NaCl with 0.05 mg trypsin (Worthington Bio-UL18-HM exists as a complex with the ALPHAILRL peptide, as
chemical) at 378C for 3 hr. Cleavage products were isolated on asuggested by its high thermal stability and confirmed by N-terminal
Uno Q anion exchange column. Two peaks were recovered andsequencing of acid eluates of purified UL18-HM (data not shown).
identified as D1 and D2 by matrix-assisted, laser desorption, time-Far UV CD spectra of the empty UL18-CC, peptide-filled UL18-
of-flight mass spectrometric analyses (molecular mass of D1,CC, and UL18-HM are similar to each other (data not shown) and
11122.5 Da; molecular mass of D2, 7516.4 Da) and N-terminal se-to previously published spectra of UL18 and class I molecules
quencing (D1 sequence, GHLPKPTLWAE; D2 sequence, IKPTL(Chapman and Bjorkman, 1997).
SAQPPV) (data not shown). D1 begins at the first residue of D1D2
and is predicted from the mass spectrometry-derived molecularExpression and Purification of Class I
weight and the N-terminal sequence of D2 to end after residue 99, aand Class I±like Molecules
tyrosine. (Cleavage after tyrosine is usually caused by chymotrypticSoluble HLA-B*2702/b2m heterodimers containing a mixture of en-
activity in trypsin preparations.) D1 contains all of the first Ig-likedogenous peptides were expressed in CHO cells and purified as
domain and four residues of the second domain as defined by Cos-described (Raghavan et al., 1996).
man et al. (1997). D2 begins at residue 100 (an isoleucine) andSoluble HLA-Cw*0702 (residues 1±274 of the mature protein com-
ends at Arg-169, as determined from the mass spectrometry-derivedplexed with human b2m) was expressed in baculovirus-infected in-
molecular weight. No evidence of contamination with uncleavedsect cells as described for UL18-HM. HLA-Cw*0702 was purified
D1D2 was found by either mass spectrometry or N-terminal se-from infected cell supernatants after adding a Cw*0702-specific
quence analyses of purified D1 or D2.peptide (AYADFVYAY) (Sidney et al., 1995) by Ni-NTA chromatogra-
D3 and D3D4 were expressed in CHO cells as described for UL18-phy followed by gel filtration using a Superdex 200 column (Phar-
CC. Constructs encoding D3 (residues 198±295) or D3D4 (residuesmacia).
198±396), each with a C-terminal 6x-His tag, were subcloned intoTruncated HLA-E and HLA-G1 (residues 1±275 of the mature pro-
a modified version of pBJ5-GS, which included the hydrophobictein containing a C-terminal 6x-His tag) were expressed in Esche-
leader sequence from rat IgG2a upstream of the multiple cloningrichia coli as described (Garboczi et al., 1996) (H. Shen and P. J. B.,
site (W. L. Martin, H. Shen, and P. J. B., unpublished data). Cellunpublished data). HLA-E and HLA-G1 were refolded from inclusion
lines secreting D3 or D3D4 were identified after precipitation ofbodies together with human b2m (expressed in E. coli using a plas-
transfected cell supernatants with Ni-NTA beads. D3 and D3D4 weremid provided by Drs. D. N. Garboczi and D. C. Wiley) and the appro-
priate peptides (VMAPRTVLL for HLA-E [Braud et al., 1997] or purified as described for HLA-Cw*0702.
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Far UV CD spectra of D1-D4, D1D2, D3D4, and D3 were similar were fit to a binding model that assumes a single class of noninter-
acting binding sites in a 1:1 binding interaction. Equilibrium dissocia-and demonstrated that each fragment was folded and composed
of mainly b-sheet secondary structure (data not shown). Transition tion constants (KDs) were derived from the ratios of rate constants
(ka and kd) as KD 5 kd/ka. For binding interactions involving class Imidpoints (Tms) derived from CD-monitored thermal denaturation
curves ranged from 578C to 718C (data not shown), demonstrating proteins, HFE, FcRn, and ZAG, we derived KDs using an equilibrium-
based approach that is not affected by mass transport effects. Forthat all fragments are folded.
these experiments, we used long injection times (15±40 min) with
slow flow rates (5 ml/min) over biosensor chips coupled to high
CD Analyses densities (1500±2000 RU), and the binding reactions were allowed
An AVIV 62A DS spectropolarimeter equipped with a thermoelectric to closely approach or to reach equilibrium. KDs were derived bycell holder was used for CD measurements. Samples containing 10 nonlinear regression analysis of plots of Req (the equilibrium binding
mM protein in 5 mM phosphate at pH 7 were used for wavelength response) versus the log of the injected protein concentration, and
scans (0.1 mm path length cell) and thermal denaturation curves the data were fit to a 1:1 binding model as described (LebroÂ n et al.,
(1.0 mm path length cell). Heat-induced unfolding of D1-D4, smaller 1998). Comparison of the kinetics-based versus equilibrium-based
LIR-1 fragments, or the various forms of UL18 were monitored by methods for determining KDs demonstrated that both methodsrecording the CD signal at 223, while the sample temperature was yielded comparable values for the same binding interaction (LebroÂ n
raised from 258C to 758C at a rate of approximately 0.78C/min. Tms et al., 1998).
were determined by taking the maximum of a plot of du/dT versus
T (where u is ellipticity) after averaging the data with a moving
Expression of UL18, HLA-B*0702, HFE, and Domain-Swappedwindow of five points.
Proteins on the Surface of COS-7 Cells
Full-length cDNAs corresponding to wild-type UL18, HLA-B*0702,
Determination of D1-D4/UL18 Stoichiometry or HFE were subcloned into the expression vector PBJ5-GS (UL18
Protein concentrations were determined spectrophotometrically at and HLA-B*0702) or PBJ1-neo (HFE). Genes encoding the following
280 nm using the following extinction coefficients: D1-D4, 43543 fusion proteins were prepared using PCR: a1a2UL18-a3HFE (UL18
M21cm21; UL18-HM, 64951 M21cm21, derived as described (LebroÂ n hydrophobic leader sequence plus residues 1±188 fused to HFE
et al., 1998). For determining the LIR-1/UL18 stoichiometry by gel residues 182±345); a1a2HFE-a3UL18 (HFE hydrophobic leader se-
filtration, molar ratios from 1:3 (300 pmol D1-D4:900 pmol UL18- quence plus residues 1±181 fused to UL18 residues 189±349);
HM) to 3:1 (900 pmol D1-D4:300 pmol UL18-HM) of D1-D4 and UL18- a1a2B7-a3HFE (HLA-B*0702 hydrophobic leader sequence plus
HM were incubated for 30 min at room temperature in 20 mM Tris residues 1±180 fused to HFE residues 182±345); and a1a2HFE-a3B7
(pH 7.4), 150 mM NaCl, and 0.05% NaN3, in a total volume of 100 (HFE hydrophobic leader sequence plus residues 1±181 fused to
ml. Samples were injected onto a Superose 6 column (Pharmacia) HLA-B*0702 residues 181±341). (The numbering system for HFE is
and eluted with the same buffer at 0.5 ml/minute. The composition from LebroÂ n et al. [1998]). Bridge PCR products were subcloned
of each fraction was analyzed by SDS-PAGE (data not shown). after sequencing into PBJ5-GS. The expression vectors were co-
Sedimentation equilibrium analytical ultracentrifugation was per- transfected into COS-7 cells (ATCC) with a human b2m expression
formed with a Beckman Optima XL-A analytical ultracentrifuge, us- vector (Fahnestock et al., 1992) using a Superfect procedure (Qia-
ing data analysis software provided by the manufacturer. Separate gen). Transfected cells were maintained in a minimal essential me-
solutions of D1-D4, UL18-HM, and D1-D4/UL18-HM, each at 0.6 dium (Irvine Scientific) supplemented with 5% dialyzed fetal bovine
mg/ml, were centrifuged for $36 hr at 208C with a rotor speed of serum (GIBCO BRL), 2 mM glutamine, penicillin (100 U/ml), and
10,000 rpm. Molecular masses were determined by nonlinear least streptomycin (100 mg/ml) for 48 hr, at which point protein expression
squares fits of the equilibrium gradients (absorbance versus radius) was assayed by cell staining (see below).
using the model of single ideal species (Hansen et al., 1994), and
partial specific volumes of 0.725 (D1-D4), 0.724 (UL18-HM), and
Immunofluorescence0.725 (D1-D4/UL18-HM), calculated from the amino acid composi-
Transfected cells were washed three times with growth mediumtion and the carbohydrate content (Zamyatnin, 1972).
and twice with phosphate-buffered saline, 0.52 mM MgCl2, and 0.9
mM CaCl2 (PBS-MC). Cells were stained after fixing to increase the
signal or stained live and then fixed to verify cell surface expression.Biosensor-Based Affinity Measurements
A Biacore 2000 biosensor system (Pharmacia LKB Biotechnology) For fixed cell staining, cells were incubated for 10 min in 2.5% (v/v)
paraformaldehyde in PBS-MC and then washed twice with PBS-was used to assay interactions between UL18 or class I molecules
and D1-D4 or fragments of LIR-1. Binding between a molecule cou- MC and once with PBS-MC containing 1% (w/v) BSA (BSA buffer).
Live cells or fixed cells were incubated with primary antibody, D1-pled to a biosensor chip and a second molecule injected over the
chip results in changes in the SPR signal that are read out in real D4, or LIR-1 Fc (see below) in BSA buffer for 15±30 min on ice (live
cells) or at room temperature (fixed cells) followed by two washestime as resonance units (RU) (Karlsson and FaÈ lt, 1997). UL18, class
I, D1-D4, or LIR-1 fragments were covalently immobilized at pH 5.5 with PBS-MC and one wash with BSA buffer. Secondary antibody
incubations were done in BSA buffer for 30 min at 48C followed byon a CM5 chip (Pharmacia LKB Biotechnology) using standard
amine coupling chemistry as described in the Biacore manual. three washes with PBS-MC. Live cells were fixed after staining in
100% methanol at 2208C for 15 min. Following staining, cells wereHigher coupling densities were achieved by increasing the time of
exposure of the protein solutions to the activated flowcell. Proteins mounted in Fluoromount (Southern Biotechnology Association) con-
taining n-propyl gallate to reduce photobleaching and viewed in awere injected over coupled biosensor chips at room temperature
in 50 mM PIPES (pH 7.0), 150 mM NaCl, and 0.005% Biacore surfac- Zeiss Axiophot fluorescent microscope. Images were recorded us-
ing software written by S. E. Fraser, J. Stollberg, and G. R. Belfordtant P20. All samples were purified by size exclusion chromatogra-
phy to minimize SPR signal resulting from aggregated protein. All (Biological Imaging Center, Caltech) on an Imaging Technology se-
ries 151 image processor. All experiments were repeated four timesinjections were followed by an identical injection onto a mock-cou-
pled flowcell or a flowcell coupled with an irrelevant protein in order with similar results.
Expression was assayed by incubating transfected cells with ato subtract out significant nonspecific responses.
Binding interactions between UL18 and all species of LIR-1 were 1:10 dilution of a rabbit anti-UL18 antiserum (Chapman and Bjork-
man, 1997; for wild-type UL18, a1a2UL18-a3HFE, or a1a2HFE-assayed using short injection times (2±4 min) with fast flow rates
(100 ml/min) over biosensor chips coupled to low densities (z100 a3UL18) or 50 ml of 1:10 dilution of a rabbit anti-HFE antiserum (J. A.
LebroÂ n and P. J. B., unpublished data; for wild-type HFE, a1a2B7-RU) (kinetics-based approach). These conditions were chosen to
minimize mass transport effects upon the kinetics of the binding a3HFE, or a1a2HFE-a3B7) followed by labeling with 50 ml of a FITC-
conjugated donkey anti-rabbit antiserum (15 mg/ml) (Jackson Immu-reactions (Karlsson and FaÈ lt, 1997). Kinetic constants were derived
from sensorgram data using BIAevaluation version 3.0, which simul- noResearch). HLA-B*0702 expression was assayed by staining with
50 ml FITC-labeled W6/32 (20 mg/ml) (Sigma), a mouse monoclonaltaneously fits the association and dissociation phases of the sen-
sorgrams and globally fits all curves in the working set. Sensorgrams antibody that recognizes human class I MHC molecules (Parham et
Immunity
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al., 1979). Untransfected cells were stained under equivalent condi- crystallization of the T-cell glycoprotein CD2. Protein Eng. 6,
229±232.tions (data not shown).
For cells expressing wild-type UL18 or UL18 domains, D1-D4 Fahnestock, M.L., Tamir, I., Narhi, L., and Bjorkman, P.J. (1992).
binding was assayed by incubating transfected and nontransfected Thermal stability comparison of purified empty and peptide filled
control cells with 50 ml of His-tagged D1-D4 (100 mg/ml), followed forms of a class I MHC molecule. Science 258, 1658±1662.
by addition of 50 ml of a murine anti-His-tag monoclonal antibody Fahnestock, M.L., Johnson, J.L., Feldman, R.M.R., Neveu, J.M.,
(20 mg/ml) (Qiagen) and then 50 ml of a Cy3-labeled donkey anti- Lane, W.S., and Bjorkman, P.J. (1995). The MHC class I homolog
mouse antiserum (3 mg/ml) (Jackson ImmunoResearch). For cells encoded by human cytomegalovirus binds endogenous peptides.
expressing wild-type HFE, wild-type B*0702, or B7 domains, D1-D4 Immunity 3, 583±590.
binding was assayed by incubating with 50 ml of LIR-1 Fc (100 mg/
Fan, Q.R., Mosyak, L., Winter, C.C., Wagtmann, N., Long, E.O., and
ml) (gift of D. Cosman, Immunex) followed by 50 ml of Cy3-labeled Wiley, D.C. (1997). Structure of the inhibitory receptor for human
goat anti-human IgG antiserum (3 mg/ml) (Jackson ImmunoRe- natural killer cells resembles haematopoietic receptors. Nature 389,
search). (Results of staining fixed cells expressing UL18 and UL18- 96±100.
containing domains with the D1-D4 reagent are shown in Figure
Fanger, N.A., Cosman, D., Peterson, L., Braddy, S.C., Maliszewski,4A. Equivalent results were obtained by staining with the LIR-1 Fc
C.R., and Borges, L. (1998). The MHC class I binding proteins LIR-1reagent; data not shown).
and LIR-2 inhibit Fc receptor-mediated signaling in monocytes. Eur.
J. Immunol. 28, 3423±3434.
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